Evidence Hub

A generative AI multi-agent framework with integrated XAI governance for cancer diagnostics: from multi-omics interpretation to lifestyle risk stratification

Barki C, Chouchen M, Sediri A, Ceylan Hİ, Rahmouni HB, Muntean RI, El-Seedi HR, Bragazzi NL et al.

Frontiers in systems biology, 2026

Abstract

Background: Cancer diagnostics is being reshaped by rapid advances in artificial intelligence, yet a persistent gap separates computational performance from clinical trust. Systematic reviews confirm that 83% of XAI studies in oncology excluded clinicians from development or evaluation, 87% lacked rigorous assessment of XAI explanations, and no universally accepted quality metrics for XAI outputs currently exist. Concurrently, generative AI (GenAI) is entering oncology at an unprecedented pace, yet it operates largely without formal interpretability governance.

Aim: This review aimed to (i) synthesize the documented gaps in XAI applications for cancer diagnostics from peer-reviewed literature, (ii) evaluate the state and limitations of GenAI in oncological settings, and (iii) propose a conceptual framework of three GenAI-powered, XAI-governed agents designed to address these gaps within a systems biology context.

Review findings: A narrative synthesis of peer-reviewed literature published between 2020 and 2026 across PubMed, Scopus, and Web of Science identified four critical, recurrent gaps: systematic exclusion of clinicians from XAI development, the absence of standardized evaluation metrics, incomplete cross-omics explanations, and the near absence of lifestyle-driven XAI models for cancer risk. GenAI is accelerating in oncology but introduces additional safety concerns, including hallucinations, non-deterministic outputs, and the illusion of transparency through…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free